Lilly 3Q Revenues: $4.9 billion (-16%) 3Q Earnings: $500.6 million (-58%) YTD Revenues: $14.5 billion (-16%)  YTD Earnings: $2.0 billion (-50%) Comments: Results in the quarter were impacted by U.S. patent expirations for Cymbalta (-73% to $368.0 million) and Evista (-65% to $89.5 million), partially offset by volume growth other products. Humalog sales increased 15% to $706.1 million. Cialis sales increased 8% to $568.4 million. Humulin sales increased 9% to $335.9 million. Forteo sales we...